Cunesoft joins forces with Phlexglobal
The Munich-based Cunesoft GmbH, an provider of cloud-based intelligent regulatory data management software and services for the life sciences industry, announced that it has been acquired by Phlexglobal from current investors including Bayern Kapital, High-Tech Gründerfonds and OCCIDENT.
Phlexglobal joins forces with Cunesoft, which expands the company’s portfolio of best-of-breed technologies designed to provide solution-specific functionality to meet the business objectives of life sciences companies. Phlexglobal is backed by Vitruvian Partners, an international private equity firm headquartered in London backing high-growth companies.
“The entire Cunesoft team is very excited about this new chapter in our story”, said Rainer Schwarz, Cunesoft co-founder and Chief Executive Officer. “Phlexglobal has a long history of providing expert services and leading software technology to its customers, and this will allow us to build on the work we have already done to advance and automate many of the processes crucial to the management of data for life-saving drugs and medical devices.”
“We will be offering customers two levels of immediate benefits with this acquisition”, said Phlexglobal CEO John McNeill. “First, we will be providing a suite of solutions that will unify the relevant processes and data elements between the Clinical Operations and Regulatory departments of life sciences companies, combining our years of thought leadership in eTMF with Cunesoft’s expertise in regulatory matters. Second, and just as important, we will be leveraging Cunesoft’s Distiller solution to package that expertise into digitalized offerings to not only augment our own suite of solutions but to operate with any existing set of solutions that might already be in place.”
Daniel Koppers, Cunesoft co-founder and CTO said: “I am very excited to combine our innovative regulatory software technologies with Phlexglobal’s eTMF solutions. ‘From trial to file’ is a great solution theme and our customers will love it.”
Bayern Kapital and High-Tech Gründerfonds invested in Cunesoft during its seed round in 2014, OCCIDENT joined as lead investor during a series A round in 2016. All investors have accompanied the young company in its development from a promising software start-up to a valued partner for the international Life Sciences industry with a sophisticated software solution.
Dr. Bernd Goergen, partner with High-Tech Gründerfonds who were invested into Cunesoft since 2014, comments: “Sometimes it seems hard to let a portfolio company go, but at the same time we are happy about having contributed for more than 5 years to the success story of Cunesoft. Moreover we share the founders’ excitement to even further accelerate the international growth of their unique software solutions for the regulated markets as a part of Phlexglobal.”
Dr. Georg Ried, Managing Director of Bayern Kapital, says: “When we invested in Cunesoft during its seed round more than five years ago, we were convinced of its technology, its talented team and its market potential. We are delighted that Cunesoft proved itself when it comes to all these aspects and developed into a successful company with international reach and a convincing solution for a high-profile client base. We believe that with support from Phlexglobal, Cunesoft has found the right partner to reach the next level of its development.”
Cédric Barra, Investment Manager with OCCIDENT, adds: “As one of the investors, we are particularly pleased to have acted as an enabler for Cunesoft and are proud to have supported the digital progress of large-scale data management in the healthcare sector. We are happy to see Phlexglobal being the perfect partner for the founders and the further internationalization of Cunesoft’s unique solution. We congratulate on this great success.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Model system provides insight into the growth of pancreatic tumors - Researchers develop innovative organoid model to study pancreatic cancer
Tobacco_BY-2_cells
Charley_horse
Recipharm completes strategic acquisition in India
Cellino aims to significantly expand patient access to cell therapies with autonomous end-to-end manufacturing - Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing
A sweet solution to a cracking problem: Scientists design new bio-Inspired molecules to promote bone regeneration - An interdisciplinary team developed novel bio-inspired sugar-based molecules that show potential to improve bone regeneration
Paper-based test could diagnose Lyme disease at early stages
A stronghold in the fight against viruses - new bacterial immune system decoded - International research team describes for the first time the structure and function of the Zorya system
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
Thermo Fisher Scientific Opens New Global Headquarters
Evangelical_School_for_the_Deaf
